| Pharmaceuticals Industry | Healthcare Sector | Mr. Rongzhao Qiu CEO | XSHE Exchange | CNE100000H10 ISIN |
| CN Country | 1,019 Employees | 3 Jul 2020 Last Dividend | 24 May 2016 Last Split | 30 Oct 2009 IPO Date |
Chongqing Lummy Pharmaceutical Co., Ltd. is a prominent pharmaceutical company founded in 1999 and based in Chongqing, China. The company is dedicated to the research and development, manufacture, and distribution of a wide range of pharmaceutical products within the Chinese market. With a focus on addressing a vast spectrum of healthcare needs, Chongqing Lummy Pharmaceutical Co., Ltd. has established a significant presence in the pharmaceutical industry, offering solutions in numerous therapeutic areas from antibacterial treatments to nutritional supplements.
These products are designed to treat various infections caused by bacteria, fungi, and viruses, playing a crucial role in managing infectious diseases.
This category includes supplements and medications intended to maintain or restore the body's ideal pH balance, thereby supporting overall health and well-being.
These products are formulated to support liver health and function, essential for detoxifying the body and metabolizing substances.
Traditional Chinese Medicine (TCM) formulations that offer a range of therapeutic benefits, based on centuries-old knowledge and practices.
These are intravenous solutions administered to provide essential nutrients, treat dehydration, or serve as vehicles for other medications.
A natural herbal supplement known for its antioxidant and energizing properties, often used to enhance physical and mental well-being.
These oncology products are aimed at treating various types of cancer, employing different mechanisms to inhibit tumor growth and spread.
A broad range of medications targeting diseases and conditions affecting the digestive, immune, hematologic, nervous, cardiovascular, and endocrine systems, addressing a wide array of health issues.
A solution used in medical emergencies to correct acidosis and to treat conditions requiring an increase in plasma bicarbonate concentrations.